SAN SALVADOR (Reuters) - The COVID-19 vaccine developed jointly by British drugmaker AstraZeneca and Oxford University was approved for use in El Salvador on Wednesday, according to a statement by the national medicines agency.
The one-page statement noted the approval was based on evidence provided by the developer but also cited emergency use permissions authorized by other countries for the vaccine.
It added that the Central American country’s health ministry will later announce the timeline and process by which it plans to distribute the vaccine.
Reporting by Nelson Renteria; Writing by David Alire Garcia; Editing by Chris Reese
Our Standards: The Thomson Reuters Trust Principles.